Company profile
Gesynta Pharma AB
Developing innovative therapies for pain and inflammation in serious diseases. Vipoglanstat in Phase 2 for endometriosis
- Industry
- Pharmaceutical Manufacturing
- Employees
- 24
- Headquarters
- Stockholm, Stockholm County
- Founded
- 2017
- LinkedIn followers
- 2,563
- Office locations
- 1
Gesynta Pharma AB company summary
Gesynta Pharma AB is a company in the Pharmaceutical Manufacturing industry, headquartered in Stockholm, Stockholm County, founded in 2017. On LinkedIn the company has around 24 employees and 2,563 followers. Its listed specialties include Endometriosis, Anti-inflammatory, mPGES-1, Arthritis, Inflammatory pain.
What technology does Gesynta Pharma AB use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Gesynta Pharma AB
Gesynta Pharma is a clinical-stage pharmaceutical company developing innovative treatments by targeting mPGES-1*, an important pro-inflammatory enzyme with a key role in endometriosis. Gesynta Pharma's research originated at Karolinska Institutet in Sweden. The company's leading compound, vipoglanstat, is a selective mPGES-1* inhibitor being developed as a new non-hormonal, non-opioid treatment with disease-modifying potential. Vipoglanstat is currently in Phase 2 clinical trials for endometriosis - a painful, chronic inflammatory disorder affecting about 10% of women of reproductive age. The condition often leads to a markedly reduced quality of life, particularly as many existing treatments fail to provide adequate symptom relief. Vipoglanstat has shown potent mPGES-1 inhibition and a favorable safety profile across Phase 1 and 2 clinical trials. Furthermore, a preclinical proof-of-concept study in an advanced model of endometriosis demonstrated that vipoglanstat significantly reduced pain-related behaviors and endometriotic lesions. A second drug candidate in the Gesynta Pharma portfolio, GS-073, is ready to enter clinical Phase 1 for the treatment of chronic inflammatory pain. The company's shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, Linc, HealthCap, XGen Venture, and other internationally renowned specialist investors. *mPGES-1: microsomal Prostaglandin E Synthase-1
Specialties
Where is Gesynta Pharma AB located?
Gesynta Pharma AB lists 1 location.
Compare companies similar to Gesynta Pharma AB
More companies in Pharmaceutical Manufacturing.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Gesynta Pharma AB gesynta.se | Pharmaceutical Manufacturing | 24 | 2017 | Stockholm, Stockholm County |
 Anacor Pharmaceuticals pfizer.com | Pharmaceutical Manufacturing | 108,102 | - | New York, New York |
 Sanofi sanofi.com | Pharmaceutical Manufacturing | 93,352 | - | Paris, France, FR |
 GSK gsk.com | Pharmaceutical Manufacturing | 92,179 | - | London, England |
 Novartis España novartis.com | Pharmaceutical Manufacturing | 85,373 | - | Basel, Baselstadt |
 AstraZeneca astrazeneca.com | Pharmaceutical Manufacturing | 80,667 | - | Cambridge, Cambridgeshire, GB |
 Eli Lilly and Company lilly.com | Pharmaceutical Manufacturing | 57,202 | - | Indianapolis, Indiana |
 Merck merck.us | Pharmaceutical Manufacturing | 44,794 | - | Rahway, New Jersey |
 SUN PHARMA sunpharma.com | Pharmaceutical Manufacturing | 47,764 | 1983 | Mumbai, Maharastra |
 Boehringer Ingelheim boehringer-ingelheim.com | Pharmaceutical Manufacturing | 47,150 | - | Ingelheim am Rhein, Rhineland-Palatinate |
 Cipla cipla.com | Pharmaceutical Manufacturing | 51,911 | - | Mumbai, Maharashtra |
Frequently asked questions about Gesynta Pharma AB
What does Gesynta Pharma AB do?
Gesynta Pharma is a clinical-stage pharmaceutical company developing innovative treatments by targeting mPGES-1*, an important pro-inflammatory enzyme with a key role in endometriosis. Gesynta Pharma's research originated at Karolinska Institutet in Sweden. The company's leading compound, vipoglanstat, is a selective mPGES-1* inhibitor being developed as a new non-hormonal, non-opioid treatment with disease-modifying potential. Vipoglanstat is currently in Phase 2 clinical trials for endometriosis - a painful, chronic inflammatory disorder affecting about 10% of women of reproductive age. The condition often leads to a markedly reduced quality of life, particularly as many existing treatments fail to provide adequate symptom relief. Vipoglanstat has shown potent mPGES-1 inhibition and a favorable safety profile across Phase 1 and 2 clinical trials. Furthermore, a preclinical proof-of-concept study in an advanced model of endometriosis demonstrated that vipoglanstat significantly reduced pain-related behaviors and endometriotic lesions. A second drug candidate in the Gesynta Pharma portfolio, GS-073, is ready to enter clinical Phase 1 for the treatment of chronic inflammatory pain. The company's shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, Linc, HealthCap, XGen Venture, and other internationally renowned specialist investors. *mPGES-1: microsomal Prostaglandin E Synthase-1
How many employees does Gesynta Pharma AB have?
Gesynta Pharma AB has around 24 employees on LinkedIn.
Where is Gesynta Pharma AB headquartered?
Gesynta Pharma AB is headquartered in Stockholm, Stockholm County.
When was Gesynta Pharma AB founded?
Gesynta Pharma AB was founded in 2017.
Build a lead list from companies like Gesynta Pharma AB
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.